Recent News

• 12.10.2025 - Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
• 12.08.2025 - Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
• 12.06.2025 - Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
• 12.05.2025 - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 11.07.2025 - Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 11.03.2025 - Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
• 10.29.2025 - Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
• 10.22.2025 - Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
• 10.18.2025 - FTX-6274, an EED Inhibitor, Demonstrates Robust Efficacy in Castration Resistant Prostate Cancer (CRPC)

Recent Filings

• 12.08.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.08.2025 - EX-99.1 EX-99.1
• 12.08.2025 - 8-K Current report
• 12.08.2025 - 144 Report of proposed sale of securities
• 11.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.19.2025 - 144 Report of proposed sale of securities
• 11.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.29.2025 - EX-99.1 EX-99.1
• 10.29.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.29.2025 - 8-K Current report